力生製藥(002393.SZ)：間接控股股東國有股權無償劃轉獲天津津聯投資控股批覆
格隆匯11月24日丨力生製藥(002393.SZ)公佈，2019年10月31日，公司間接控股股東天津市醫藥集團有限公司(“醫藥集團”)與天津渤海國有資產經營管理有限公司(“渤海國資”)簽署了《津聯集團有限公司100%股權無償劃轉協議》；同日，金鼎控股有限公司(“金鼎控股”)與天津醫藥集團國際控股有限公司(“醫藥集團BVI公司”)簽署了《隆騰有限公司33%股權無償劃轉協議》。上述劃轉協議中約定，醫藥集團將其持有的津聯集團有限公司100%股權無償劃轉至渤海國資；同時，金鼎控股將其持有的隆騰有限公司33%股權無償劃轉至醫藥集團BVI公司。
2019年11月22日，公司收到天津市醫藥集團有限公司轉來的天津津聯投資控股有限公司《關於津聯集團100%股權、隆騰公司33%股權無償劃轉的批覆》：
一、同意天津市醫藥集團有限公司將持有的津聯集團有限公司(簡稱津聯集團)100%股權無償劃轉至天津渤海國有資產經營管理有限公司。本次無償劃轉為同一集團項下國有企業間的內部整合，不涉及任何商業性質的股權轉讓交易。截至劃轉基準日2018年12月31日，津聯集團總資產約291.41億港元，總權益約149.20億港元。
二、同意金鼎控股有限公司將持有的隆騰有限公司(簡稱隆騰公司)33%股權無償劃轉至天津醫藥集團國際控股有限公司。本次無償劃轉為同一集團項下國有企業間的內部整合，不涉及任何商業性質的股權轉讓交易。截至劃轉基準日2018年12月31日，隆騰公司總資產約79.97億港元，總權益約67.38億港元。
此次無償劃轉完成後，醫藥集團不再為公司的間接控股股東，渤海國資仍為公司的間接控股股東。劃轉完成後，公司的控股股東不變，仍為天津金浩醫藥有限公司(“金浩公司”)，金浩公司對公司的持股數量及比例未發生變化；公司的實際控制人不變，仍為天津市人民政府國有資產監督管理委員會。
此次無償劃轉尚需向中國證券監督管理委員會申請渤海國資豁免要約收購公司股份的義務後方可生效。因此，此次無償劃轉能否順利實施尚存在重大不確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
